Canaccord Genuity initiates coverage of Seaport Therapeutics with buy rating, $28 price target
SPTX•Canaccord Genuity initiated coverage of Seaport Therapeutics with a buy rating and a $28 price target.
Related News
Vir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal
VIR•
Nasdaq halts JZ trading for volatility at 9:30 a.m.
JZ•
Oncolytics Biotech expects final GOBLET Cohort 4 results in Q4 2026
ONCY•
Apple asks US court to overturn landmark $5.7 billion patent verdict
AAPL•
Stem announces third-quarter earnings conference call
STEM•